Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma (Q42317543)

25 October 2017

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma (English)

1 reference

25 October 2017

17

Meenhard Herlyn

1 reference

25 October 2017

Mizuho Fukunaga-Kalabis

16

object named as

Mizuho Fukunaga-Kalabis

1 reference

25 October 2017

4

Adina Vultur

1 reference

25 October 2017

1

Clemens Krepler

1 reference

25 October 2017

Katherine L Nathanson

15

object named as

Katherine L Nathanson

1 reference

25 October 2017

11

Denitsa Hristova

1 reference

25 October 2017

3

Minu Samanta

1 reference

25 October 2017

Patricia I Reyes-Uribe

7

object named as

Patricia I Reyes-Uribe

1 reference

25 October 2017

6

Patricia Brafford

1 reference

25 October 2017

Min Xiao

2

1 reference

25 October 2017

Hsin-Yi Chen

5

1 reference

25 October 2017

Molly Halloran

8

1 reference

25 October 2017

Thomas Chen

9

1 reference

25 October 2017

Xu He

10

1 reference

25 October 2017

Qin Liu

12

1 reference

25 October 2017

Ahmed A Samatar

13

1 reference

25 October 2017

Michael A Davies

14

1 reference

25 October 2017

Jessie Villanueva

18

1 reference

25 October 2017

language of work or name

English

0 references

publication date

16 September 2016

1 reference

25 October 2017

1 reference

25 October 2017

7

1 reference

25 October 2017

44

1 reference

25 October 2017

71211-71222

1 reference

Targeting RAS-ERK signalling in cancer: promises and challenges

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch3 pathway alterations in ovarian cancer.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Major therapeutic developments and current challenges in advanced melanoma

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

25 October 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

High NOTCH activity induces radiation resistance in non small cell lung cancer

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

The Notch signaling pathway as a mediator of tumor survival

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

A landscape of driver mutations in melanoma

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

ERK inhibition overcomes acquired resistance to MEK inhibitors.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch Signaling and Breast Cancer

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch signaling: simplicity in design, versatility in function

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Targeting Notch signaling pathway to overcome drug resistance for cancer therapy

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Active Notch1 confers a transformed phenotype to primary human melanocytes

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch1 is an effector of Akt and hypoxia in melanoma development

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

The many facets of Notch ligands

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Mutations of the BRAF gene in human cancer

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma

25 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

High-throughput oncogene mutation profiling in human cancer

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5342073

Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27655717

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.12078

1 reference

25 October 2017

1 reference

25 October 2017

PubMed publication ID

27655717

1 reference